Búsqueda | Biblioteca Virtual en Salud

1.

Dual-energy x-ray absorptiometry: interpreting reports and serial measurements.

Bonnick, Sydney L.

Clin Obstet Gynecol ; 56(4): 677-85, 2013 Dec.

Artículo en Inglés | MEDLINE | ID: mdl-24022500

2.

Descriptive analysis of concomitant prescription medication patterns from 1999 to 2004 among US women receiving daily or weekly oral bisphosphonate therapy.

Gold, Deborah T; Bonnick, Sydney Lou; Amonkar, Mayur M; Kamel, Hosam K; Agarwal, Shuchita; Zaidi, Mone.

Gend Med ; 5(4): 374-84, 2008 Dec.

Artículo en Inglés | MEDLINE | ID: mdl-19108810

3.

Bone Densitometry for Technologists

Bonnick, Sydney Lou.

New York, NY; Springer New York;Imprint: Springer; 2013. 421 p.

Monografía en Inglés | Bibliografia | ID: bib-341058

4.

HSA: beyond BMD with DXA.

Bonnick, Sydney Lou.

Bone ; 41(1 Suppl 1): S9-12, 2007 Jul.

Artículo en Inglés | MEDLINE | ID: mdl-17459802

5.

Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years.

Bonnick, Sydney; Saag, Kenneth G; Kiel, Douglas P; McClung, Michael; Hochberg, Marc; Burnett, Sherri-Ann M; Sebba, Anthony; Kagan, Risa; Chen, Erluo; Thompson, Desmond E; de Papp, Anne E.

J Clin Endocrinol Metab ; 91(7): 2631-7, 2006 Jul.

Artículo en Inglés | MEDLINE | ID: mdl-16636120

6.

Going on a drug holiday?

Bonnick, Sydney Lou.

J Clin Densitom ; 14(4): 377-83, 2011.

Artículo en Inglés | MEDLINE | ID: mdl-22051091

7.

Osteoporosis in men and women.

Bonnick, Sydney L.

Clin Cornerstone ; 8(1): 28-39, 2006.

Artículo en Inglés | MEDLINE | ID: mdl-17591574

8.

Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study.

Rosen, Clifford J; Hochberg, Marc C; Bonnick, Sydney L; McClung, Michael; Miller, Paul; Broy, Susan; Kagan, Risa; Chen, Erluo; Petruschke, Richard A; Thompson, Desmond E; de Papp, Anne E.

J Bone Miner Res ; 20(1): 141-51, 2005 Jan.

Artículo en Inglés | MEDLINE | ID: mdl-15619680

9.

Treatment satisfaction in postmenopausal women suboptimally adherent to bisphosphonates who transitioned to denosumab compared with risedronate or ibandronate.

Palacios, Santiago; Agodoa, Irene; Bonnick, Sydney; Van den Bergh, Joop P; Ferreira, Irene; Ho, Pei-Ran; Brown, Jacques P.

J Clin Endocrinol Metab ; 100(3): E487-92, 2015 Mar.

Artículo en Inglés | MEDLINE | ID: mdl-25514106

10.

Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis.

Sebba, Anthony I; Bonnick, Sydney Lou; Kagan, Risa; Thompson, Desmond E; Skalky, Carol S; Chen, Erluo; de Papp, Anne E.

Curr Med Res Opin ; 20(12): 2031-41, 2004 Dec.

Artículo en Inglés | MEDLINE | ID: mdl-15706659

11.

Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: a randomized placebo-controlled trial.

Bonnick, Sydney; De Villiers, Tobias; Odio, Alberto; Palacios, Santiago; Chapurlat, Roland; DaSilva, Carolyn; Scott, Boyd B; Le Bailly De Tilleghem, Celine; Leung, Albert T; Gurner, Deborah.

J Clin Endocrinol Metab ; 98(12): 4727-35, 2013 Dec.

Artículo en Inglés | MEDLINE | ID: mdl-24064689

12.

Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial.

Recknor, Chris; Czerwinski, Edward; Bone, Henry G; Bonnick, Sydney L; Binkley, Neil; Palacios, Santiago; Moffett, Alfred; Siddhanti, Suresh; Ferreira, Irene; Ghelani, Prayashi; Wagman, Rachel B; Hall, Jesse W; Bolognese, Michael A; Benhamou, Claude-Laurent.

Obstet Gynecol ; 121(6): 1291-1299, 2013 Jun.

Artículo en Inglés | MEDLINE | ID: mdl-23812464

13.

Patient satisfaction in postmenopausal women treated with a weekly bisphosphonate transitioned to once-monthly ibandronate.

Bonnick, Sydney Lou; Silverman, Stuart; Tanner, S Bobo; Martens, Mark; Bachmann, Gloria; Kohles, Joseph D; Civitelli, Roberto.

J Womens Health (Larchmt) ; 18(7): 935-43, 2009 Jul.

Artículo en Inglés | MEDLINE | ID: mdl-19563245

14.

Monitoring changes in bone density.

Bonnick, Sydney Lou.

Womens Health (Lond) ; 4: 89-97, 2008 Jan.

Artículo en Inglés | MEDLINE | ID: mdl-19072454

15.

Noninvasive assessments of bone strength.

Bonnick, Sydney Lou.

Curr Opin Endocrinol Diabetes Obes ; 14(6): 451-7, 2007 Dec.

Artículo en Inglés | MEDLINE | ID: mdl-17982351

16.

Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density.

Bonnick, Sydney; Broy, Susan; Kaiser, Fran; Teutsch, Carol; Rosenberg, Elizabeth; DeLucca, Paul; Melton, Mary.

Curr Med Res Opin ; 23(6): 1341-9, 2007 Jun.

Artículo en Inglés | MEDLINE | ID: mdl-17594775

17.

Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both?

Bonnick, Sydney Lou; Shulman, Lee.

Am J Med ; 119(4 Suppl 1): S25-31, 2006 Apr.

Artículo en Inglés | MEDLINE | ID: mdl-16563938

18.

Bone Densitometry in Clinical Practice : Application and Interpretation

Bonnick, Sydney Lou.

Totowa, NJ; Humana Press;Imprint: Humana Press; 2010.

Monografía en Inglés | Bibliografia | ID: bib-343258

19.

Current controversies in bone densitometry.

Bonnick, Sydney Lou.

Curr Opin Rheumatol ; 14(4): 416-20, 2002 Jul.

Artículo en Inglés | MEDLINE | ID: mdl-12118178

20.

Clinical value of monitoring BMD in patients treated with bisphosphonates for osteoporosis.

Watts, Nelson B; Lewiecki, E Michael; Bonnick, Sydney L; Laster, Andrew J; Binkley, Neil; Blank, Robert D; Geusens, Piet P; Miller, Paul D; Petak, Steven M; Recker, Robert R; Saag, Kenneth G; Schousboe, John; Siris, Ethel S; Bilezikian, John P.

J Bone Miner Res ; 24(10): 1643-6, 2009 Oct.

Artículo en Inglés | MEDLINE | ID: mdl-19712042

Biblioteca Virtual en Salud

Hipertensión

Su selección (0)

Formato de exportación:

Exportar:

Dual-energy x-ray absorptiometry: interpreting reports and serial measurements.

Descriptive analysis of concomitant prescription medication patterns from 1999 to 2004 among US women receiving daily or weekly oral bisphosphonate therapy.

Bone Densitometry for Technologists

HSA: beyond BMD with DXA.

Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years.

Going on a drug holiday?

Osteoporosis in men and women.

Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study.

Treatment satisfaction in postmenopausal women suboptimally adherent to bisphosphonates who transitioned to denosumab compared with risedronate or ibandronate.

Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis.

Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: a randomized placebo-controlled trial.

Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial.

Patient satisfaction in postmenopausal women treated with a weekly bisphosphonate transitioned to once-monthly ibandronate.

Monitoring changes in bone density.

Noninvasive assessments of bone strength.

Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density.

Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both?

Bone Densitometry in Clinical Practice : Application and Interpretation

Current controversies in bone densitometry.

Clinical value of monitoring BMD in patients treated with bisphosphonates for osteoporosis.